他汀、安慰剂与无治疗交叉试验中的副作用模式
本研究纳入曾停用他汀的参与者,采用12个月交叉设计,每月随机使用阿托伐他汀20mg、安慰剂或空瓶,通过app每日记录症状强度。结果显示,他汀月与安慰剂月的症状评分均显著高于无药月,但两者之间无差异,提示多数他汀相关症状为反安慰剂效应。
要点
- 他汀月与安慰剂月的症状评分均显著高于无药月,但两者无差异。
- 反安慰剂比值为0.90,提示多数他汀相关症状由反安慰剂效应引起。
- 临床不应根据症状强度或发生/缓解时机判断他汀的药理因果关系。
核心结论
- 他汀片剂引起的大多数症状为反安慰剂效应。
- 临床不应将症状强度或症状发生/缓解时机解释为他汀的药理因果关系,因为安慰剂模式相同。
研究设计与样本
- 随机交叉试验,参与者接受12个1个月药瓶,其中4瓶含阿托伐他汀20mg,4瓶安慰剂,4瓶空瓶。
- 共60名参与者随机化,49名完成12个月方案。
- 使用app每日测量症状强度(量表1-100)。
主要发现
- 无药月平均症状评分为8.0(95%CI:4.7-11.3)。
- 他汀月平均症状评分为16.3(95%CI:13.0-19.6;P<0.001),高于无药月。
- 安慰剂月平均症状评分为15.4(95%CI:12.1-18.7;P<0.001),高于无药月。
- 他汀月与安慰剂月症状评分无差异(P=0.388)。
- 反安慰剂比值为0.90。
临床怎么用
- 临床医生不应将症状强度或症状发生/缓解时机解释为他汀的药理因果关系。
- 对于报告他汀副作用患者,应考虑反安慰剂效应的可能性。
局限性
- 样本量较小(60名随机化,49名完成)。
- 研究对象为曾停用他汀的参与者,可能限制普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most people who begin statins abandon them, most commonly because of side effects. OBJECTIVES: The purpose of this study was to assess daily symptom scores on statin, placebo, and no treatment in participants who had abandoned statins. METHODS: Participants received 12 1-month medication bottles, 4 containing atorvastatin 20 mg, 4 placebo, and 4 empty. We measured daily symptom intensity for each using an app (scale 1-100). We also measured the "nocebo" ratio: the ratio of symptoms induced by taking statin that was also induced by taking placebo. RESULTS: A total of 60 participants were randomized and 49 completed the 12-month protocol. Mean symptom score was 8.0 (95% CI: 4.7-11.3) in no-tablet months. It was higher in statin months (16.3; 95% CI: 13.0-19.6; P < 0.001), but also in placebo months (15.4; 95% CI: 12.1-18.7; P < 0.001), with no difference between the 2 (P = 0.388). The corresponding nocebo ratio was 0.90. In the individual-patient daily data, neither symptom intensity on starting (OR: 1.02; 95% CI: 0.98-1.06; P = 0.28) nor extent of symptom relief on stopping (OR: 1.01; 95% CI: 0.98-1.05; P = 0.48) distinguished between statin and placebo. Stopping was no more frequent for statin than placebo (P = 0.173), and subsequent symptom relief was similar between statin and placebo. At 6 months after the trial, 30 of 60 (50%) participants were back taking statins. CONCLUSIONS: The majority of symptoms caused by statin tablets were nocebo. Clinicians should not interpret symptom intensity or timing of symptom onset or offset (on starting or stopping statin tablets) as indicating pharmacological causation, because the pattern is identical for placebo. (Self-Assessment Method for Statin Side-effects Or Nocebo [SAMSON]; NCT02668016).
引用
- Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021. PMID: 34531021. doi:10.1016/j.jacc.2021.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。